US FDA classifies Biocon Biologics site as VAI
The VAI classification was given to Biocon Biologics’ Insulins facilities in Johor Bahru, Malaysia
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Malaysia
Venus Remedies gains Malaysian PIC/S GMP approval for pre-filled syringe facility
The accreditation facilitates quicker approvals across the ASEAN region and opens new global business opportunities for Venus…
MoH, Malaysia, awards three-year contract to Biocon Biologics’s Insugen
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices…
Biocon gets three observations from US health regulator for Malaysia facility
The FDA has set a target action date for its insulin glargine application in June 2020